Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

  • 1,250 21 mei 2024 17:31
  • -0,030 (-2,34%) Dagrange 1,250 - 1,305
  • 10.715 Gem. (3M) 16,8K

Relief therapeutics Holding

9.103 Posts
Pagina: «« 1 ... 67 68 69 70 71 ... 456 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 18 augustus 2020 08:03
    quote:

    Zittenblijvertje schreef op 17 augustus 2020 22:51:

    [...]Nee hoor zoals eerder te lezen viel in een bericht van cash , zijn alle rechten in handen van Relief . En hebben in het recente verleden nog geprobeerd om dit medicijn voor een prikkie te slijten
    NeuroRX voert alle testen uit en vraag merknamen aan, dus het is duidelijk dat NeuroRX wel degelijk bepaalde rechten heeft en dus een flink gedeelte van de evt. opbrengst krijgt.
  2. forum rang 10 DeZwarteRidder 18 augustus 2020 08:37
    Optimism on Covid-19 immunity climbs as studies show antibodies protect and T-cells last longer

    Fishing boat study provides first real-life example of antibodies in action

    17 August 2020 • 7:00pm

    Scientists are growing increasingly confident about the human immune response to SARS-CoV-2 after studies showed antibodies provide “real-world” protection against the virus and cellular immunity may be long-lasting, even in mild cases.

    A study of a Covid-19 outbreak on a Seattle fishing boat involving more than 100 sailers has all but proven that antibodies provide protection against re-infection. Meanwhile, an encouraging body of evidence has found that T and B cells remain in the blood even once antibodies fade.

    “This is exactly what you would hope for,” Marion Pepper, an immunologist at the University of Washington and an author on one of the new studies, told The New York Times. “All the pieces are there to have a totally protective immune response.”

    “This is very promising,” echoed Smita Iyer, an immunologist at the University of California, Davis “This calls for some optimism about herd immunity, and potentially a vaccine.”

    Antibodies have long been thought to protect against reinfection but the first study to use hard real-world evidence was published last week by researchers at the University of Washington.

    It tracked the 122 strong crew of a fishing boat operating in the Pacific off the coast of Seattle, Washington. All were tested for both antibodies and the virus before they sailed and after. An outbreak occurred on the vessel and 104 people become infected - an attack rate of 85 per cent.

    However, only those without pre-existing antibodies caught the virus. Of the three crew members who had already been exposed to the disease prior to the boat’s departure and had antibodies, none showed evidence of reinfection.

    Professor Danny Altmann, of the department of immunology and inflammation at Hammersmith Hospital, Imperial College, said: "While this is a small study, it offers a remarkable, real-life, human experiment at a time when we've been short of hard-line, formal, proof that neutralising antibodies genuinely offer protection from re-infection. In short, it’s good news”.

    While the findings are welcome news, key questions remain over the human immune responses to the virus - namely around how long such antibodies last. Most studies show they start to fade after just a few months.

    However, there is mounting evidence that T cells and B cells, often described as “memory cells”, provide longer-lasting protection.

    It was widely reported last month that researchers at the Karolinska University Hospital and University Hospital of Wales had found that people who recovered from asymptomatic or mild cases of Covid-19 may have long-term T-cell immunity against severe infection.

    Similarly, another Seattle-based study published just last week found that patients who had recovered from mild forms of the virus had developed SARS-CoV-2-specific antibodies and neutralizing plasma, as well as virus-specific memory B and T cells.

    These “memory cells” not only persisted but in some cases increased numerically over the three months following symptom onset.

    According to the study, the T cells multiplied upon re-encounter with the virus, while the B cells expressed receptors “capable of neutralising the virus”.

    As such, the authors claim that the findings demonstrate that even mild Covid-19 can elicit memory cells that provide protective immunity.

    www.telegraph.co.uk/global-health/
  3. [verwijderd] 18 augustus 2020 08:50
    quote:

    DeZwarteRidder schreef op 18 augustus 2020 08:37:

    Optimism on Covid-19 immunity climbs as studies show antibodies protect and T-cells last longer

    Fishing boat study provides first real-life example of antibodies in action

    17 August 2020 • 7:00pm

    Scientists are growing increasingly confident about the human immune response to SARS-CoV-2 after studies showed antibodies provide “real-world” protection against the virus and cellular immunity may be long-lasting, even in mild cases.

    A study of a Covid-19 outbreak on a Seattle fishing boat involving more than 100 sailers has all but proven that antibodies provide protection against re-infection. Meanwhile, an encouraging body of evidence has found that T and B cells remain in the blood even once antibodies fade.

    “This is exactly what you would hope for,” Marion Pepper, an immunologist at the University of Washington and an author on one of the new studies, told The New York Times. “All the pieces are there to have a totally protective immune response.”

    “This is very promising,” echoed Smita Iyer, an immunologist at the University of California, Davis “This calls for some optimism about herd immunity, and potentially a vaccine.”

    Antibodies have long been thought to protect against reinfection but the first study to use hard real-world evidence was published last week by researchers at the University of Washington.

    It tracked the 122 strong crew of a fishing boat operating in the Pacific off the coast of Seattle, Washington. All were tested for both antibodies and the virus before they sailed and after. An outbreak occurred on the vessel and 104 people become infected - an attack rate of 85 per cent.

    However, only those without pre-existing antibodies caught the virus. Of the three crew members who had already been exposed to the disease prior to the boat’s departure and had antibodies, none showed evidence of reinfection.

    Professor Danny Altmann, of the department of immunology and inflammation at Hammersmith Hospital, Imperial College, said: "While this is a small study, it offers a remarkable, real-life, human experiment at a time when we've been short of hard-line, formal, proof that neutralising antibodies genuinely offer protection from re-infection. In short, it’s good news”.

    While the findings are welcome news, key questions remain over the human immune responses to the virus - namely around how long such antibodies last. Most studies show they start to fade after just a few months.

    However, there is mounting evidence that T cells and B cells, often described as “memory cells”, provide longer-lasting protection.

    It was widely reported last month that researchers at the Karolinska University Hospital and University Hospital of Wales had found that people who recovered from asymptomatic or mild cases of Covid-19 may have long-term T-cell immunity against severe infection.

    Similarly, another Seattle-based study published just last week found that patients who had recovered from mild forms of the virus had developed SARS-CoV-2-specific antibodies and neutralizing plasma, as well as virus-specific memory B and T cells.

    These “memory cells” not only persisted but in some cases increased numerically over the three months following symptom onset.

    According to the study, the T cells multiplied upon re-encounter with the virus, while the B cells expressed receptors “capable of neutralising the virus”.

    As such, the authors claim that the findings demonstrate that even mild Covid-19 can elicit memory cells that provide protective immunity.

    www.telegraph.co.uk/global-health/
  4. thewitte 18 augustus 2020 09:14
    quote:

    Zwartgeld schreef op 18 augustus 2020 08:56:

    [...]Jij wakkert zo veel angst in mensen.
    Waneer ze een stukje van jou negatieve analyse proeven men meteen verkoopt .
    Heb al mee gemaakt met wirecard .
    Heb me hoop geld gekost.
    Nu met dit....

    Quote je nu jezelf? Of val je hier door de mand door met je verkeerde alias te reageren..
  5. forum rang 10 DeZwarteRidder 18 augustus 2020 09:17
    quote:

    Zwartgeld schreef op 18 augustus 2020 08:56:

    [...]Jij wakkert zo veel angst in mensen.
    Waneer ze een stukje van jou negatieve analyse proeven men meteen verkoopt .
    Heb al mee gemaakt met wirecard .
    Heb me hoop geld gekost.
    Nu met dit....
    Je teksten zijn nogal onduidelijk, maar ik wil er nog wel even op wijzen dat ik vorig jaar toen de koers van Wirecard ruim boven de 100 stond, keihard heb gewaarschuwd voor de fraude bij Wirecard.

    Helaas hebben weinig personen zich daar iets van aangetrokken.
  6. Hangyodon 18 augustus 2020 09:26
    quote:

    Kleintje66 schreef op 18 augustus 2020 09:20:

    Vanmorgen toch maar 80% verkocht. Ga rustig afwachten of er weer grote partijen verkocht worden waardoor de prijs gedrukt wordt en anders lekker genieten van de gemaakte winst.
    hoop ik voor je dat je boven de 50c hebt verkocht en niet onderaan 0.45
9.103 Posts
Pagina: «« 1 ... 67 68 69 70 71 ... 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links